David Friedman Recent News
GW Pharma Soars 35% on Initiation from Morgan Stanley, Bullish Comments by Jim Cramer
UPDATE: Morgan Stanley Reiterates on Synageva BioPharma as Brain-Blood Barrier Study is Good Next Step
UPDATE: Morgan Stanley Reiterates on Chimerix as New AdV Trial Highlights Broad Brincidofovir Potential
UPDATE: Morgan Stanley Downgrades Auxilium Pharmaceuticals as Growth May Not Match High Valuation
UPDATE: Morgan Stanley Initiates Coverage on Ultragenyx Pharmaceutical on Growing Orphan Drug Pipeline
Morgan Stanley Expects Theravance to Continue to Underperform Following 4Q Earnings
UPDATE: Morgan Stanley Downgrades Alnylam Pharmaceuticals, Sees Robust Drug Prospects
UPDATE: Morgan Stanley Downgrades Neurocrine Biosciences on Recent Stock Appreciation
UPDATE: Morgan Stanley Initiates Coverage on Relypsa on Large Opportunity in K+ Control
Morgan Stanley Reiterates Equal-Weight Rating on InterMune Following 2Q Sales Results
UPDATE: Morgan Stanley Initiates Portola Pharmaceuticals at Overweight on Drugs Potentially Fulfilling Serious Medical Need
UPDATE: Morgan Stanley Initiates Alnylam Pharmaceuticals at Overweight on Market Leader Position
UPDATE: Morgan Stanley Initiates Alnylam Pharmaceuticals at Overweight on Positively Viewed Amyloidosis Program
UPDATE: Morgan Stanley Downgrades XenoPort on Recent Failures
UPDATE: Morgan Stanley Downgrades Lexicon Pharmaceuticals on Challenged Valuation